

INTERNATIONAL ENCYCLOPEDIA  
OF PHARMACOLOGY AND THERAPEUTICS  
Section 124

# **The Role of Calcium in Drug Action**

Editor:  
**M. A. DENBOROUGH**

PERGAMON PRESS

INTERNATIONAL ENCYCLOPEDIA OF  
PHARMACOLOGY AND THERAPEUTICS

Section 124

# THE ROLE OF CALCIUM IN DRUG ACTION

SECTION EDITOR

**M. A. DENBOROUGH**

*Australian National University, Canberra, Australia*



Y078691



**PERGAMON PRESS**

OXFORD · NEW YORK · BEIJING · FRANKFURT  
SÃO PAULO · SYDNEY · TOKYO · TORONTO

U.K.	Pergamon Press, Headington Hill Hall, Oxford OX3 0BW, England
U.S.A.	Pergamon Press, Maxwell House, Fairview Park, Elmsford, New York 10523, U.S.A.
PEOPLE'S REPUBLIC OF CHINA	Pergamon Press, Qianmen Hotel, Beijing, People's Republic of China
FEDERAL REPUBLIC OF GERMANY	Pergamon Press, Hammerweg 6, D-6242 Kronberg, Federal Republic of Germany
BRAZIL	Pergamon Editora, Rua Eça de Queiros, 346, CEP 04011, São Paulo, Brazil
AUSTRALIA	Pergamon Press Australia, P.O. Box 544, Potts Point, N.S.W. 2011, Australia
JAPAN	Pergamon Press, 8th Floor, Matsuka Central Building, 1-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160, Japan
CANADA	Pergamon Press Canada, Suite 104, 150 Consumers Road, Willowdale, Ontario M2J 1P9, Canada

---

Copyright © 1987 Pergamon Books Ltd.

*All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means: electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers.*

First edition 1987

#### **Library of Congress Cataloging in Publication Data**

The Role of calcium in drug action.

(International encyclopedia of pharmacology and therapeutics; section 124)

"Published as supplement no. 24. (1986) to the review journal *Pharmacology and therapeutics*"—T.p. verso. Includes bibliographies and index.

1. Calcium—Metabolism—Regulation.

2. Calcium—Agonists—Therapeutic use.

3. Calcium—Antagonists—Therapeutic use.

I. Denborough, Michael, 1929— II. Pharmacology & therapeutics. III. Series. [DNLM: I. Calcium—metabolism.

2. Calcium—pharmacodynamics QV 4 158 section 124]

QP535.C2R644 1986 615'.7 86-16965

#### **British Library Cataloguing in Publication Data**

The Role of calcium in drug action.—

(International encyclopedia of pharmacology and therapeutics; section 124)

1. Calcium—Physiological effect

2. Drugs—Physiological effect

I. Denborough, M. A. II. Pharmacology and therapeutics III. Series

615'.7 QP913.C2

ISBN 0-08-034193-4

Published as Supplement No. 24 (1987) to the review journal *Pharmacology and Therapeutics*. Papers appearing in this volume are revised, updated versions of papers previously published in the journal.

*Executive Editor: W. C. BOWMAN, Glasgow*

Section 124

58 THE ROLE OF CALCIUM IN DRUG ACTION

## EDITORIAL BOARD

D. BOVET, <i>Rome</i>	G. B. KOELLE, <i>Philadelphia</i>
W. C. BOWMAN, <i>Glasgow</i>	P. LECHAT, <i>Paris</i>
A. M. BRECKENRIDGE, <i>Liverpool</i>	H. RASKOVA, <i>Prague</i>
A. S. V. BURGEN, <i>London</i>	A. C. SARTORELLI, <i>New Haven</i>
J. CHEYMOL, <i>Paris</i>	V. V. ZAKUSOV, <i>Moscow</i>

### Some Recent and Forthcoming Volumes

- 114 BALFOUR  
Nicotine and the Tobacco Smoking Habit
- 115 MITCHELL  
The Modulation of Immunity
- 116 SHUGAR  
Viral Chemotherapy, Volume 2
- 117 De WIED, GISPEN and van WIMERSMA GREIDANUS  
Neuropeptides and Behaviour, Volume 1
- 118 GOLDMAN  
Membrane Transport of Antineoplastic Agents
- 119 DORNER and DREWS  
Pharmacology of Bacterial Toxins
- 120 IHLER  
Methods of Drug Delivery
- 121 DETHLEFSEN  
Cell Cycle Effects
- 122 ROWLAND and TUCKER  
Pharmacokinetics: Theory and Methodology
- 123 De WIED, GISPEN and van WIMERSMA GREIDANUS  
Neuropeptides and Behaviour, Volume 2
- 124 DENBOROUGH  
The Role of Calcium in Drug Action
- 125 GRUNBERGER and GOFF  
Mechanisms of Cellular Transformation by Carcinogenic Agents
- 126 WEBBE  
The Toxicology of Molluscicides

### NOTICE TO READERS

Dear Reader

If your library is not already a standing order customer to this series, may we recommend that you place a standing order to receive immediately on publication all new volumes published in this valuable series. Should you find that these volumes no longer serve your needs your order can be cancelled at any time without notice.

The Editors and Publisher will be glad to receive suggestions or outlines of suitable titles for consideration for rapid publication in this series.

Robert Maxwell

*Publisher at Pergamon Press*

## PREFACE

The free cytosolic  $\text{Ca}^{2+}$  ion concentration controls many cellular functions, and an abnormality in the concentration of intracellular  $\text{Ca}^{2+}$  can lead to profound metabolic effects. Take, for example, the anaesthetic complication malignant hyperpyrexia. The clinical features of malignant hyperpyrexia are diverse and include muscular rigidity, a rapid and sustained rise in body temperature and metabolic acidosis. These all result from an elevated myoplasmic  $\text{Ca}^{2+}$  concentration which develops when an abnormal muscle cell membrane is exposed to an anaesthetic such as halothane. The chance observation that a drug, dantrolene sodium, lowers myoplasmic  $\text{Ca}^{2+}$  concentration, led to the use of dantrolene sodium as a specific and effective treatment for malignant hyperpyrexia. Dantrolene sodium is but one example of a drug which acts by its effect on the cytoplasmic  $\text{Ca}^{2+}$  concentration, and in this volume the actions of drugs on cytosolic  $\text{Ca}^{2+}$  concentrations in relation to a variety of other human cells and clinical problems are reviewed. Disorders of red blood cells, platelets, the heart, bone, hypertension and asthma may be linked by a common factor—disturbance of intracellular calcium regulation.

The level of cytoplasmic  $\text{Ca}^{2+}$  concentration depends on the amount of  $\text{Ca}^{2+}$  released from intracellular storage sites and on the amount of  $\text{Ca}^{2+}$  entering the cell through channels in the surface membrane. As our knowledge increases about these two mechanisms as a result of detailed physiological and biochemical investigations, it seems very likely that the range of pharmacological agents which can alter the mechanisms will expand, and have a significant role in preventing and treating a wide variety of human diseases.

M. A. Denborough

April, 1986

## LIST OF CONTRIBUTORS

N. G. Ardlie  
Department of Medicine & Clinical Science  
The Australian National University  
Central Health Laboratory Building  
Woden Valley Hospital  
Canberra  
ACT 2600  
Australia

F. L. Bygrave  
Department of Biochemistry  
Faculty of Science  
Australian National University  
Canberra  
ACT 2600  
Australia

B. R. Creese  
Department of Medicine & Clinical Science  
John Curtin School of Medical Research  
Australian National University  
Canberra  
ACT 2600  
Australia

S. Lipe  
Department of Medicine & Department of Clinical Pharmacology & Therapeutics  
The University of Melbourne  
The Royal Melbourne Hospital  
Parkville  
Victoria 3050  
Australia

T. J. Martin  
Department of Medicine  
The University of Melbourne  
West Heidelberg  
Repatriation General Hospital  
Victoria 3081  
Australia

K. E. McCulloch  
Department of Haematology  
Austin Hospital  
Heidelberg  
Victoria 3084  
Australia

M. K. McNamara  
Department of Haematology  
Austin Hospital  
Heidelberg  
Victoria 3084  
Australia

R. F. W. Moulds  
Department of Medicine & Department of Clinical Pharmacology & Therapeutics  
The University of Melbourne  
The Royal Melbourne Hospital  
Parkville  
Victoria 3050  
Australia

L. H. Opie  
Heart Research Unit and Hypertension Clinic  
Department of Medicine  
Medical School  
Observatory 7925  
South Africa

P. H. Reinhart  
Department of Biochemistry  
Faculty of Science  
Australian National University  
Canberra  
ACT 2600  
Australia

W. M. Taylor  
Department of Biochemistry  
Faculty of Science  
Australian National University  
Canberra  
ACT 2600  
Australia

J. S. Wiley  
Department of Haematology  
Austin Hospital  
Heidelberg  
Victoria 3084  
Australia

## CONTENTS

### LIST OF CONTRIBUTORS

xiii

#### 1. CALCIUM IONS, DRUG ACTION AND THE RED CELL MEMBRANE

J. S. WILEY, K. E. MCCULLOCH and M. K. MCNAMARA, Austin Hospital,  
Victoria, Australia

1. Introduction	1
2. Calcium pump	2
2.1 Kinetics and the stoichiometry of the pump	3
2.2 Energy requirements	4
2.3 Calmodulin (CaM) stimulation	4
2.4 Effect of Drugs	5
3. Calcium influx into erythrocytes	6
3.1 Quantitation of unidirectional influx	6
3.2 Evidence for facilitated $\text{Ca}^{2+}$ influx	8
3.3 Effects of drugs	9
4. Effect of calcium on morphology and membrane biochemistry	9
4.1 Erythrocyte shape changes	9
4.2 Lipid changes	10
4.3 Calcium activated $\text{K}^+$ efflux	11
4.4 Effect on membrane proteins and cytoskeleton	12
5. Clinical syndromes with abnormal calcium fluxes	13
5.1 Sickle cell anemia	13
5.2 Hereditary hemolytic anemia with red cell fragmentation	14
5.3 Cold-stored erythrocytes	15
5.4 Thalassemia and other conditions with marrow stress	16
6. Summary	16
References	17

#### 2. CALCIUM IONS, DRUG ACTION AND PLATELET FUNCTION

N. G. ARDLIE, The Australian National University, Canberra, Australia

1. Introduction	23
2. The role of calcium in platelet adhesion and platelet-platelet interaction	23
3. Calcium homeostasis in unstimulated platelets	25
4. Calcium movements in platelet activation	26
4.1 Changes in cytoplasmic free calcium in stimulated platelets	26
4.2 Release of calcium from platelet dense granules	29
4.3 Changes in surface-bound calcium	29
5. Biochemical events in the calcium messenger system	30
6. Effects of intracellular calcium in platelets	32
6.1 Activation of phospholipases	32
6.2 Protein phosphorylation	33
6.3 Disassembly of microtubules	34
6.4 Membrane fusion in the release reaction	34
6.5 Other effects of calcium	34
7. Calmodulin and platelet activation	35

8. Interrelationships between calcium and cyclic AMP in inhibition of platelet activation	35
9. Drugs, calcium ions and platelet activation	36
9.1 Calcium channel blockers	37
9.2 Inhibitors of calmodulin	37
9.3 Calcium antagonists and other drugs	38
9.4 Drugs that increase cyclic AMP	38
10. Summary	39
References	40
 3. CALCIUM IONS, DRUG ACTION AND AIRWAYS OBSTRUCTION	51
B. R. CREESE, Australian National University, Canberra, Australia	
1. Introduction	51
1.1 Airways smooth muscle in asthma	51
1.2 The role of allergic reactions in asthma	52
2. Calcium ions and airways smooth muscle	53
2.1 Smooth muscle regulation by calcium ions	53
2.2 Airways smooth muscle	54
3. Calcium ions and the release of allergic mediators	56
3.1 The involvement of calcium ions in mediator release	56
3.2 Regulation of calcium ion movements in mast cells	58
3.3 Sites of calcium ion action in mast cells	59
4. Cyclic nucleotide and arachidonic acid metabolism	61
5. Calcium ions and drug action	62
5.1 Anti-asthmatic drugs	62
5.2 Calcium antagonistic drugs	63
References	64
 4. CALCIUM, DRUG ACTION AND HYPERTENSION	71
S. LIPE and R. F. W. MOULDS, University of Melbourne, Australia	
1. Calcium ions and contraction of vascular smooth muscle	71
1.1 Introduction	71
1.2 Animal studies	72
1.3 Human studies	77
2. Drug effects and calcium ions in vascular smooth muscle	80
2.1 Introduction	80
2.2 Animal studies	80
2.3 Human blood vessels	89
3. Hypertensive blood vessels	92
3.1 Introduction	92
3.2 Role of calcium in contraction of vascular smooth muscle in hypertension	93
3.3 Drugs in hypertension	95
3.4 Conclusion	95
References	96
 5. CALCIUM IONS, DRUG ACTION AND THE HEART	103
L. H. OPIE, University of Cape Town, South Africa	
1. Definition of calcium channel blockers	103
2. Pharmacological aspects	104
2.1 Sarcolemmal binding sites	104
2.2 Indirect interaction with beta-adrenoceptor	105
2.3 Mode of action of beta-adrenoceptor antagonists contrasted with calcium channel blockers	106

2.4	Mode of action of calcium channel blockers	106
2.5	Projected model for calcium channel	106
2.6	Functionally different calcium channels?	109
2.7	Possible intracellular effects	110
2.8	Non-specific effects on receptor and ions	110
3.	Physiological aspects: calcium ion movements as sites of action	111
3.1	Calcium ion flux in heart muscle	111
3.2	Peripheral vascular arterial muscle	112
3.3	Coronary artery smooth muscle and coronary spasm	113
3.4	Nodal tissue	114
4.	Experimental effects	114
4.1	Effects on physiological processes	114
4.2	Prevention of catecholamine-invoked injury	114
4.3	Inhibition of ischemic injury	114
4.4	Ventricular fibrillation	115
4.5	Molecular explanation for beta-adrenergic effects which are limited or prevented by calcium channel blockers	116
4.6	Arterial calcinosis	116
4.7	Diabetic eye cataracts	116
4.8	Experimental cardiomyopathy	117
5.	Classification of calcium channel blockers	117
5.1	Binding sites	117
5.2	Functional classification	117
6.	Clinical indications for calcium channel blockers	117
6.1	Chronic stable angina of effort	117
6.2	Angina caused by coronary spasm	118
6.3	Angina at rest	118
6.4	Acute myocardial infarction	119
6.5	Supraventricular arrhythmias	119
6.6	Hypertension	120
6.7	Obstructive cardiomyopathy	120
6.8	Congestive heart failure	120
6.9	Pulmonary hypertension	121
6.10	Raynaud's phenomenon	121
6.11	Cerebral insufficiency	121
6.12	Peripheral vascular disease	121
6.13	Bronchospasm	121
6.14	Diuretic effects	121
6.15	Migraine	121
7.	Some comparative clinical properties	122
7.1	Verapamil	122
7.2	Nifedipine	122
7.3	Diltiazem	123
7.4	Verapamil compared with nifedipine	123
7.5	Verapamil compared with diltiazem	123
7.6	Diltiazem compared with nifedipine	124
8.	Mixed sodium-calcium channel blockers	124
8.1	Lidoflazine	124
8.2	Bepridil	125
8.3	Tiapamil	125
9.	New analogs of existing agents	125
10.	Other calcium channel blockers	126
10.1	Prenylamine	126
10.2	Perhexilene	126
11.	Drug interactions and combinations	126

11.1	Negative inotropic potential	126
11.2	Combination with beta-adrenoceptor antagonists	126
11.3	Digoxin	127
11.4	Prazosin	127
11.5	Quinidine	127
11.6	Combination with nitrates	128
11.7	Combination with ACE inhibitors	128
12.	Side-effects	128
12.1	Verapamil	128
12.2	Nifedipine	129
12.3	Diltiazem	129
12.4	Other agents	129
12.5	Side-effects: conclusions	130
13.	Contraindications	130
14.	Summary	130
	References	131
6.	ON THE ROLE OF CALCIUM IN THE MECHANISM OF ACTION OF ALPHA-ADRENERGIC AGONISTS IN RAT LIVER	139
	W. M. TAYLOR, P. H. REINHART and F. L. BYGRAVE, Australian National University, Canberra, Australia	
1.	Introduction	139
2.	Alpha-adrenergic agonists, antagonists and receptors	139
3.	Evidence for a role of $Ca^{2+}$ in hepatic alpha-agonist action	141
4.	Measurement of cellular $Ca^{2+}$ fluxes	142
5.	Pools of $Ca^{2+}$ mobilized by alpha-agonists	143
6.	Metabolic consequences of altered cellular $Ca^{2+}$ distribution	145
7.	Current views on the nature of the alpha-agonist-induced 'signal'	148
8.	Concluding comments	151
	References	151
7.	DRUG AND HORMONE EFFECTS ON CALCIUM RELEASE FROM BONE	157
	T. J. MARTIN, University of Melbourne, Australia	
1.	Introduction	157
2.	Bone structure	157
3.	Calcium homeostasis	159
3.1	Historical review	159
3.2	Parathyroid hormone and calcium homeostasis	159
3.3	Discovery of calcitonin and its action	159
3.4	The bone and calcium homeostasis	160
4.	Hormones and local factors controlling release of bone calcium	161
4.1	Parathyroid hormone	161
4.2	1,25-dihydroxyvitamin D	162
4.3	Thyroxine	163
4.4	Epidermal growth factor and transforming growth factors	163
4.5	Prostaglandins	164
4.6	Endogenous production of prostaglandins in bone	166
4.7	Osteoclast activating factor (OAF)	166
5.	Hormonal inhibitors of bone resorption	167
5.1	Calcitonin	167
5.2	Glucocorticoids	167
6.	Cellular mechanisms of bone resorption	168
6.1	Coupling between bone resorption and formation	168
6.2	Actions of bone resorbing hormones upon osteoclasts	168

6.3	Possible role of osteoblasts in the bone resorptive process	169
6.4	Cyclic AMP and bone cell function	170
7.	Effects of drugs	171
7.1	Heparin	171
7.2	Cyclic AMP analogues and phosphodiesterase inhibitors	171
7.3	Drugs influencing cellular calcium	171
7.4	Drugs influencing microtubule function	172
7.5	Vitamin A	172
7.6	Non-steroidal anti-inflammatory drugs	172
7.7	Diphosphonates	173
7.8	Mithramycin	173
8.	Summary	173
	References	174
INDEX		179

## CHAPTER 1

# CALCIUM IONS, DRUG ACTION AND THE RED CELL MEMBRANE

JAMES, S. WILEY, KATHLEEN E. MCCULLOCH and MICHAEL K. MCNAMARA

*Department of Haematology, Austin Hospital, Melbourne 3084, Victoria, Australia*

## 1. INTRODUCTION

Many unique properties of the mammalian erythrocyte make this cell among the most specialized in the body. High concentrations of hemoglobin for the carriage of oxygen, a total dependence on glycolytic metabolism and an unusual biconcave shape and flexibility have long been known. More recent studies have indicated that the ionic permeability of the erythrocyte membrane is also unique. Red cell fluxes of monovalent cations,  $\text{Na}^+$  and  $\text{K}^+$  are far lower than observed in nucleated cells while divalent cation fluxes are even lower. Analysis of intracellular calcium by atomic absorption spectroscopy has yielded values which are barely measurable and this low value reflects the few  $\text{Ca}^{2+}$ -accumulating organelles (i.e. mitochondria, endoplasmic reticulum) in the mature erythrocyte. Indeed, the ionized (free)  $\text{Ca}^{2+}$  concentration in the human red cell has recently been reported to be only  $0.2 \mu\text{M}$  measured by a null-point method with a  $\text{Ca}^{2+}$ -sensitive electrode (Simons, 1981). Considerably higher values for total red cell  $\text{Ca}^{2+}$  have been found, and most studies which have used the dry-ashing technique give a  $\text{Ca}^{2+}$  content of about 15 nmol/ml cells (Harrison and Long, 1968; Lichtman and Weed, 1972). Trace contamination by  $\text{Ca}^{2+}$  is widespread in reagents from glass bottles while even plastics may contribute  $\text{Ca}^{2+}$  to an ambient solution, presumably from the plasticizer used to impart flexibility to the material. When rigorous precautions were taken to remove  $\text{Ca}^{2+}$  from washing solutions and containers, analysis of total red cell  $\text{Ca}^{2+}$  has yielded values of only 5 nmol/ml cells (Bookchin and Lew, 1981; Wiley and Shaller, 1977). Whatever value is taken for the total red cell  $\text{Ca}^{2+}$ , it is clear that 95% or more of this cation is bound to some ligand(s). The cytoplasmic protein calmodulin, inorganic and organic phosphates and membrane phospholipids, especially di- and tri-phosphoinositides have all been shown to bind  $\text{Ca}^{2+}$  with varying affinity. When red cell  $\text{Ca}^{2+}$  is raised by addition of cells to a  $\text{Ca}^{2+}$ -medium containing the divalent cation ionophore, A23187, a significant fraction of cell  $\text{Ca}^{2+}$  (50–80%) behaves as the bound (nonionized) species even when cell  $\text{Ca}^{2+}$  is raised to the vicinity of 1 mM (Ferreira and Lew, 1976). Again the identity of this low affinity Ca-buffer of high capacity is not certain, although organic phosphates such as 2,3-diphosphoglycerate (2,3 DPG) and adenosine triphosphate (ATP) seem likely candidates.

The majority of  $\text{Ca}^{2+}$  within the erythrocyte normally appears to be membrane-bound since it separates with the stroma on centrifugation of hemolysates (Harrison and Long, 1968; Weed *et al.*, 1969; Wiley and Gill, 1976). A recent paper has demonstrated that much of this stroma-associated  $\text{Ca}^{2+}$  is associated with intracellular vesicles with an ATP-dependent capacity to accumulate this cation (Lew *et al.*, 1985). A direct function of membrane  $\text{Ca}^{2+}$  in maintaining low permeability is suggested by the action of  $\text{Ca}^{2+}$  in reversing the large increase in cation permeability which can be induced in human

erythrocytes by exposure to nonelectrolyte solutions such as lactose (Bolingbroke and Maizels, 1959). Moreover, extracellular  $\text{Ca}^{2+}$  does have small but significant effects on both  $\text{Na}^+$  and  $\text{K}^+$  influxes into human red cells which are reduced by 20–40% in the presence of 10 mM  $\text{CaCl}_2$  (Ellory *et al.*, 1980). However, perhaps the most important function of membrane  $\text{Ca}^{2+}$  is to influence the physical state of the cytoskeleton which, in turn, determines the deformability of the cell (see Section 4.4). The role of  $\text{Ca}^{2+}$  in red cell physiology has been the subject of several recent reviews (Ferreira and Lew, 1977; Parker 1981; Roufogalis, 1979; Vincenzi and Larsen, 1980).

## 2. CALCIUM PUMP

Many cells utilize  $\text{Ca}^{2+}$ -sequestering organelles such as mitochondria or endoplasmic reticulum to minimize cytoplasmic free  $\text{Ca}^{2+}$ , although a plasma membrane  $\text{Ca}^{2+}$ -pump is still necessary to maintain low cell  $\text{Ca}^{2+}$  levels. However, erythrocytes depend only on an active  $\text{Ca}^{2+}$ -pump to maintain cytoplasmic  $\text{Ca}^{2+}$  at  $< 1 \mu\text{M}$ . This pump is localized in the membrane and displays a  $\text{Mg}^{2+}$ -dependent  $\text{Ca}^{2+}$ -activated ATPase activity (EC 3.6.1.3). The initial studies of Schatzmann and Vincenzi (1969) demonstrating outward net transport of  $\text{Ca}^{2+}$  from  $\text{Ca}^{2+}$ -loaded ghosts have been amply confirmed (Lee and Shin, 1969; Olsen and Cazort, 1969). Calcium extrusion was strongly temperature dependent ( $Q_{10} = 3.5$ ) and had a pH optimum between 6.9 and 8.5. Some dependence of pumping on external cations can be demonstrated with a rank order  $\text{K}^+ > \text{Na}^+ = \text{choline} > \text{Mg}^{2+}$  for stimulation of both  $\text{Ca}^{2+}$  extrusion and  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase of ghosts (Romero, 1981; Schatzmann and Rossi, 1971; Wierichs and Bader, 1980). The  $\text{Ca}^{2+}$ -pump is capable of extruding this cation against a very large concentration gradient. Cells loaded with 0.6 mM  $\text{Ca}^{2+}$  will extrude this cation into a 110 mM  $\text{CaCl}_2$  (isotonic) medium, although the pumping rate is only half the maximal value observed with no  $\text{Ca}^{2+}$  externally (Fig. 1). No selective inhibitors of the  $\text{Ca}^{2+}$  pump have been discovered to date. However, cation analogs such as ruthenium red, vanadate,  $\text{Sr}^{2+}$  or  $\text{La}^{3+}$  do inhibit  $\text{Ca}^{2+}$  transport in a competitive fashion (Allan and Thomas, 1981b; Rossi *et al.*, 1981; Szasz *et al.*, 1978). Intracellular  $\text{Mg}^{2+}$  is a cofactor for  $\text{Ca}^{2+}$  pumping, although  $\text{Mg}^{2+}$  is not itself transported by the pump. Many studies support the view that the red cell membrane  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase and the active outward transport of  $\text{Ca}^{2+}$  are two manifestations of the same enzymatic process (Cha, *et al.*, 1977; Lee and Shin 1969; Olsen and Cazort, 1969).




FIG. 1. Calcium extrusion from fresh human erythrocytes. Cells were preloaded with  $\text{Ca}^{2+}$  at  $0^\circ\text{C}$  in a salicylate medium (see Wiley and Gill, 1976), washed and reincubated at  $37^\circ\text{C}$  in media containing 0, 5 or 110 mM  $\text{CaCl}_2$  plus NaCl to maintain isotonicity. Initial cell  $\text{Ca}^{2+}$  was  $0.6 \mu\text{mol/ml}$  cells.

## 2.1 KINETICS AND STOICHIOMETRY OF THE PUMP

A wide range of kinetic data and stoichiometries have been reported for the red cell  $\text{Ca}^{2+}$ -pump, much of which may result from differences in methodology. The majority of studies have utilized resealed ghosts or inside-out vesicles (IOV) rather than intact red cells because concentrations of substrates and cofactors can be more easily controlled. However, the kinetic properties of these systems may not necessarily be identical to those in the intact red cell. For example, sonication of ghosts in isosmotic imidazole buffer results in a large loss of  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase activity, while repeated freeze thawing has been shown to both increase and decrease  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase activity (Farrance and Vincenzi, 1977a; Meltzer and Kassir, 1981). Also, several reports suggest that exposure of IOV to dextran T-70 (or T-110) gradients results in a loss in both  $\text{Ca}^{2+}$  pumping and  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase activity (Quist and Roufogalis, 1977; Vincenzi and Larsen, 1980). The use of high ionic strength buffers, such as 310 mM (isosmotic) imidazole to prepare IOV and resealed ghosts can also cause an increase in the  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase activity. Possibly the extent of calmodulin (CaM) binding to the membrane during its preparation (see Section 2.3) could account for some of the differences in the  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase activities noted below (Farrance and Vincenzi, 1977a,b).

The results of many kinetic analyses are listed in Table 1 which shows both high and low affinities of the  $\text{Ca}^{2+}$ -pump towards both  $\text{Ca}^{2+}$  and ATP. However, the data cannot be taken as evidence for two separate  $\text{Ca}^{2+}$ -transport mechanisms, since interconvertibility of the high and low affinity transport systems has been demonstrated. Human erythrocyte IOV, devoid of CaM, demonstrate a low  $\text{Ca}^{2+}$  affinity transport component ( $K_m > 100 \mu\text{M} \text{Ca}^{2+}$ ). Binding of CaM to the IOV converted the  $\text{Ca}^{2+}$ -pump to high  $\text{Ca}^{2+}$  affinity kinetics ( $K_m 2.5 \mu\text{M} \text{Ca}^{2+}$ ; Larsen *et al.*, 1981a). In a different preparation (fragmented membranes), it has also been demonstrated that the binding of CaM alters the  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase from a low to a high  $\text{Ca}^{2+}$  affinity state (Table 1; Foder and Scharff, 1981). Clearly binding of CaM to the membrane alters the microenvironment of the  $\text{Ca}^{2+}$ -pump, although it is not certain whether the interactions of the cytoskeleton with the membrane are also affected.

Variable stoichiometry of the red cell  $\text{Ca}^{2+}$ -pump has been reported. Initial studies of  $\text{Ca}^{2+}$  extrusion by resealed red cell ghosts reported 0.8  $\text{Ca}^{2+}$  ions/ATP hydrolyzed, while subsequent work has supported a 1:1 stoichiometry for the red cell  $\text{Ca}^{2+}$ -pump, both in resealed ghosts and intact cells (Larsen *et al.*, 1978; Mualem and Karlsh, 1979; Romero, 1981; Schatzmann and Vincenzi, 1969). In two of these studies,  $\text{Ca}^{2+}$  pumping was analyzed by multiple techniques:  $\text{Ca}^{2+}$  selective glass electrodes,  $^{45}\text{Ca}^{2+}$  efflux and flame analysis by atomic absorption spectroscopy, each of which was compared to ATP splitting measured in the presence of ouabain to remove the contribution of the  $(\text{Na}^+ + \text{K}^+)$

TABLE 1. Reported Affinities for  $\text{Ca}^{2+}$  Transport and  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase

Assay	Preparation	$\text{Ca}^{2+}$ $K_m (\mu\text{M})$	$\text{Mg}^{2+}$ -ATP $K_m (\mu\text{M})$	Reference
Transport	IOV	3.4	100 1000	Mollmann and Pleasure (1980)
Transport	IOV	19	—	MacIntyre and Gunn (1981)
Transport	Intact cells	0.7–1.0	—	Ferreira and Lew (1976)
ATPase	Resealed ghost	0.9	50	Wolf (1972)
Transport and ATPase	Resealed ghost	—	1–2 180	Mualem and Karlsh (1979)
ATPase	Membranes	—	1–2	Schatzmann (1977)
ATPase	Membranes	1.1 32	—	Rega and Garrahan (1975) Foder and Scharff (1981)
Transport	IOV	2.5 100	—	Larsen <i>et al.</i> (1981a)
Transport	Resealed ghost	3 250	—	Romero (1981)

pump. Control cells under each condition included  $250\ \mu\text{M}$   $\text{La}^{3+}$  to block  $\text{Ca}^{2+}$  pumping, which allowed correction for ATP splitting independent of the  $\text{Ca}^{2+}$ -pump. However, not all investigators agree on the stoichiometry of the  $\text{Ca}^{2+}$ -pump and a ratio of 2  $\text{Ca}^{2+}$  ions/ATP hydrolyzed has been reported by Sarkadi *et al.* (1977) and Quist and Roufogalis (1975). However, these latter studies utilized lower concentrations ( $100\ \mu\text{M}$ ) of  $\text{La}^{3+}$ , and it is possible that variations in Ca-independent ATP hydrolysis or leakiness of reconstituted ghosts to internal  $\text{Ca}^{2+}$  may account for the different stoichiometric ratios which have been reported. More recent evidence suggests that the ratio of  $\text{Ca}^{2+}$  pumped:ATP hydrolyzed can vary with the level of intracellular  $\text{Ca}^{2+}$ . In an IOV preparation, a stoichiometry of 2  $\text{Ca}^{2+}$  pumped:1 ATP hydrolyzed was found with low ambient  $\text{Ca}^{2+}$  ( $<20\ \mu\text{M}$ ), while with high  $\text{Ca}^{2+}$  ( $>100\ \mu\text{M}$ ), the ratio became 1:1 (Larsen *et al.*, 1981a).

## 2.2. ENERGY REQUIREMENTS

The addition of  $\text{Ca}^{2+}$  to a suspension of ATP-replete erythrocytes had no effect on ATP levels and increased ATP breakdown by less than 20 nmol/ml cells/hr (Ferreira and Lew, 1975). This value is less than 1% of normal glycolytic ATP production whereas, in contrast, the sodium pump consumes 10–15% of red cell glycolytic energy. Artificial induction of  $\text{Ca}^{2+}$  leakiness by ionophore A23187 greatly stimulates the  $\text{Ca}^{2+}$ -pump and leads to a progressive depletion of ATP levels (Allan *et al.*, 1976; Kirkpatrick *et al.*, 1975; Lang *et al.*, 1977; Plishker and Gitelman, 1977). Various nucleotide triphosphates, other than ATP, can act as substrates for the  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase in resealed ghosts, with reported efficacy in the order  $\text{ATP} = \text{CTP} = \text{UTP} > \text{GTP} > \text{ITP}$  (Lee and Shin, 1969). Whether these triphosphates act as phosphate donors for the pump or as substrates for nucleoside diphosphokinase (thereby maintaining ATP levels) is not established.

## 2.3. CALMODULIN (CaM) STIMULATION

In 1973, Bond and Clough reported that the red blood cell  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase was activated up to 2.5-fold by crude hemolysate, due to an activator protein distinct from hemoglobin. This important discovery has led to the characterization of calmodulin which is a small, heat stable, acidic protein with a ubiquitous distribution in eukaryotic cells. Calmodulin has an important role in activating many  $\text{Ca}^{2+}$ -dependent enzymes, such as cyclic adenosine monophosphate phosphodiesterase, myosin kinase, adenylate cyclase and phosphorylase kinase, as well as the red cell calcium pump (Gopinath and Vincenzi, 1977; Jarrett and Kyte, 1979; Jarrett and Penniston, 1977; Luthra *et al.*, 1976; MacIntyre and Green, 1978). Molecular sizing by sodium dodecyl sulfate gel electrophoresis indicates that CaM is approximately 18,000 daltons and is present at a concentration of 1–3  $\mu\text{M}$  in the erythrocyte cytosol of many different species (Jarrett and Penniston, 1977; Vincenzi, 1981). It is believed that CaM has four  $\text{Ca}^{2+}$  binding sites per molecule, two of which are of high affinity and two of lower affinity for binding  $\text{Ca}^{2+}$  ions (Walsh and Stevens, 1978). Direct binding of CaM to the  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase has been reported with a 1:1 stoichiometry both in human ghosts and IOV using photoaffinity labelling with azido- $^{125}\text{I}$ -CaM (Hinds and Andreasen, 1981). The major effect of CaM is to increase the maximum velocity ( $V_{\max}$ ) of both the  $\text{Ca}^{2+}$ -pump and  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase, and stimulations ranging from 2 to 10-fold have been reported. Moreover, some studies suggest that CaM also increases the apparent affinity of the  $(\text{Ca}^{2+} + \text{Mg}^{2+})$  ATPase for  $\text{Ca}^{2+}$  ions (Al-jabore and Roufogalis, 1981; Gopinath and Vincenzi, 1977; Meltzer and Kassir, 1981; Vincenzi and Larsen, 1980).

CaM is believed to act through a two-step process:

- (1)  $\text{CaM}_{\text{inactive}} + n\text{Ca}^{2+} \rightleftharpoons (\text{CaM}^* \cdot \text{Ca}_n^{2+})_{\text{active}}$
- (2)  $(\text{CaM} \cdot \text{Ca}_n^{2+})_{\text{active}} + \text{enzyme}_{\text{less active}} \rightleftharpoons [\text{enzyme}^* \cdot (\text{CaM} \cdot \text{Ca}_n^{2+})]_{\text{active}}$

where \* represents a new conformation (Lynch and Cheung, 1979). Thus the interactions of  $\text{Ca}^{2+}$  with CaM may represent an important regulatory step in the activity of several  $\text{Ca}^{2+}$  dependent reactions.